Ustekinumab trough levels in children with Crohn’s disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use

Ustekinumab trough levels in children with Crohn’s disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use

Background: Ustekinumab is used off-label in pediatric Crohn’s disease refractory to anti-tumor necrosis factor. Data on optimal dosing, target trough levels, and potential benefit of therapeutic drug monitoring in children treated with ustekinumab are limited.Materials and Methods: We describe a se...

Full description

Bibliographic Details
Main Authors: Marleen Bouhuys, Paola Mian, Patrick F. van Rheenen
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Pharmacology
Subjects:
ustekinumab
therapeutic drug monitoring
Crohn’s disease
inflammatory bowel disease
pediatrics
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1180750/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1180750/full

Similar Items